DGIdb - PAMIDRONIC ACID Drug Record

PAMIDRONIC ACID chembl:CHEMBL834 ApprovedAntineoplastic

Alternate Names:

PAMIDRONATE
CGP-23339AE
PAMIDRONIC ACID
ACIDUM PAMIDRONICUM
AREDIA®
ACIDE PAMIDRONIQUE
ARD233
RIBODROAT
ACIDO PAMIDRONICO
drugbank:00282
rxcui:1546406
chembl:CHEMBL834
rxcui:11473
chemidplus:40391-99-9
pubchem.compound:4674

Drug Info:

Drug Class	bisphosphonates
Year of Approval	1991
FDA Approval	1991
Drug Class	small molecule
Drug Indications	Bisphosphonates

(2 More Sources)

Publications:

Conti et al., 2005, Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines., J. Immunol.
Sarasquete ME et al., 2008, Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis., Blood
Waller et al., 2004, Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy., Eur. J. Pediatr.
Riebeling et al., 2002, The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro., Br. J. Cancer
Dunford et al., 2001, Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates., J. Pharmacol. Exp. Ther.
Zhang et al., 2004, Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy., Ann. Clin. Lab. Sci.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Notarnicola et al., 2004, Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis., Oncology
Bergstrom et al., 2000, Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase., Arch. Biochem. Biophys.
Santini et al., 2002, Pamidronate induces modifications of circulating angiogenetic factors in cancer patients., Clin. Cancer Res.

PAMIDRONIC ACID FDPS

Interaction Score: 9.27

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12177810 11160603 15487700 11752352 15713990 10620343

Sources:
TdgClinicalTrial TEND TTD
PAMIDRONIC ACID CD86

Interaction Score: 3.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15611247

Sources:
NCI
PAMIDRONIC ACID CASR

Interaction Score: 2.75

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15241688

Sources:
NCI
PAMIDRONIC ACID CYP2C8

Interaction Score: 0.99

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18594024

Sources:
PharmGKB
PAMIDRONIC ACID CXCL8

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12006522

Sources:
NCI

TEND: PAMIDRONATE
- Version: 01-August-2011
Alternate Names:

PAMIDRONATE Primary Drug Name

Drug Info:

Year of Approval 1991

Drug Class bisphosphonates

Publications:
TdgClinicalTrial: PAMIDRONATE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Bisphosphonates

Drug Class small molecule

FDA Approval 1991

Publications:

NCI: PAMIDRONATE

Version: 14-September-2017

Alternate Names:

C1345 NCI drug code

Drug Info:

Publications:

Conti et al., 2005, Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines., J. Immunol.

Waller et al., 2004, Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy., Eur. J. Pediatr.

Santini et al., 2002, Pamidronate induces modifications of circulating angiogenetic factors in cancer patients., Clin. Cancer Res.

PharmGKB: pamidronate

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Sarasquete ME et al., 2008, Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis., Blood

TTD: Pamidronate
- Version: 2020.06.01
Alternate Names:

D0BF8G TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL834
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	-
Novel drug target	Established target

PAMIDRONIC ACID Drug Record

PAMIDRONIC ACID chembl:CHEMBL834 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

PAMIDRONIC ACID FDPS

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 12177810 11160603 15487700 11752352 15713990 10620343

Sources: TdgClinicalTrial TEND TTD

PAMIDRONIC ACID CD86

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15611247

Sources: NCI

PAMIDRONIC ACID CASR

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15241688

Sources: NCI

PAMIDRONIC ACID CYP2C8

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18594024

Sources: PharmGKB

PAMIDRONIC ACID CXCL8

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12006522

Sources: NCI

TEND: PAMIDRONATE

Alternate Names: PAMIDRONATE Primary Drug Name

Drug Info: Year of Approval 1991 Drug Class bisphosphonates

Publications:

TdgClinicalTrial: PAMIDRONATE

Alternate Names:

Drug Info: Drug Indications Bisphosphonates Drug Class small molecule FDA Approval 1991

Publications:

NCI: PAMIDRONATE

Alternate Names: C1345 NCI drug code

Drug Info:

PharmGKB: pamidronate

Alternate Names:

Drug Info:

Publications: Sarasquete ME et al., 2008, Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis., Blood

TTD: Pamidronate

Alternate Names: D0BF8G TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL834

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12177810 11160603 15487700 11752352 15713990 10620343

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
15611247

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15241688

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18594024

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12006522

Sources:
NCI

Alternate Names:

PAMIDRONATE Primary Drug Name

Drug Info:

Year of Approval 1991

Drug Class bisphosphonates

Drug Info:

Drug Indications Bisphosphonates

Drug Class small molecule

FDA Approval 1991

Alternate Names:

C1345 NCI drug code

Publications:

Sarasquete ME et al., 2008, Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis., Blood

Alternate Names:

D0BF8G TTD Drug ID